[Skip to Navigation]
Sign In
September 2016

Cardiovascular Monitoring With Trastuzumab Therapy: How Frequent Is Too Frequent?

Author Affiliations
  • 1Rush Medical College, Chicago, Illinois
  • 2Section of Medical Oncology, Rush University Medical Center, Chicago, Illinois
  • 3Division of Cardiology, Rush University Medical Center, Chicago, Illinois
JAMA Oncol. 2016;2(9):1123-1124. doi:10.1001/jamaoncol.2016.1288

Trastuzumab has led to meaningful improvements in survival in early-stage and metastatic ERBB2 (formerly HER2 or HER2/neu)-positive breast cancer.1,2 Trastuzumab is generally well tolerated but is associated with infrequent cardiac dysfunction, manifested most often as an asymptomatic decline in left ventricular ejection fraction (LVEF).1-6

Add or change institution